Minakem-flap
Minakem-flap

Find Drugs for Pulmonary/Respiratory Diseases in Phase I Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Human Monoclonal Antibody

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CERC-002

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Cerecor

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 29, 2021

            Details:

            ERC-002 is a first-in-class anti-LIGHT monoclonal antibody. LIGHT is homologous to lymphotoxin and exhibits an inducible expression. It competes with the HSV glycoprotein D for binding to the herpesvirus entry mediator, a receptor expressed on T lymphocytes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): rhSP-D

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AT-100

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 26, 2021

            Details:

            AT-100 is a novel human recombinant protein that has been shown in preclinical studies to reduce inflammation and infection triggered in very preterm babies by mechanical ventilation and oxygen support and ultimately reduce the onset of lung damage.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AV-001

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AV-001

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 25, 2021

            Details:

            It analysed the safety, tolerability and pharmacokinetics of AV-001 following administration of single-ascending and multiple-ascending doses up to 56µg/kg a day for seven consecutive days.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TDI01

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TDI01

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Graviton

            Deal Size: $517.5 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement February 23, 2021

            Details:

            The agreement grants development and commercialization rights for TDI01 to Graviton in all territories, excluding China.